Eli Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk

Three-year study reveals significant weight loss and potential long-term health benefits for prediabetic and obese adults.

Tirzepatide, sold as Zepbound and Mounjaro, cuts diabetes progression risk by 94% in prediabetic, obese adults.
Participants in the study lost an average of 22.9% body weight on the highest dose of the drug.
The study followed over 1,000 adults for 176 weeks, with a 17-week follow-up period after treatment ended.
Even after stopping treatment, participants had an 88% lower risk of developing diabetes compared to placebo.
Eli Lilly's stock hit a record high following the announcement of the study results.